NDC 49643-0367-05: English Walnut Pollen Juglans regia .05 g/mL Injection, 5 mL Vial
This is a package of 5 mL of English Walnut Pollen Juglans regia .05 g/mL Injection from Allermed Laboratories, Inc., first listed with the FDA Mar 1974 and currently FDA-listed. It is the main listing for this product, which comes in 4 package sizes.
NDC database record
One package, one record: these facts belong to NDC 49643-367-05 alone.
- Record
- FDA NDC Directory package listing · Non-standardized allergenic
- Code segments
- 49643 labeler · 367 product · 05 package
- Package marketed since
- Mar 12, 1974
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 4964336705 8
- FDA record last changed
- Oct 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 49643-0367-05 You're viewing this Main listing | 5 mL in 1 VIAL, MULTI-DOSE | 1974-03-12 | — | Active |
| 49643-0367-10 49643-367-10 | 10 mL in 1 VIAL, MULTI-DOSE | 1974-03-12 | — | Active |
| 49643-0367-30 49643-367-30 | 30 mL in 1 VIAL, MULTI-DOSE | 1974-03-12 | — | Active |
| 49643-0367-50 49643-367-50 | 50 mL in 1 VIAL, MULTI-DOSE | 1974-03-12 | — | Active |
You're viewing the smallest of 4 pack sizes for this product.
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 49643-0367-10?
What NDC number is used to bill for this package of English Walnut Pollen Juglans regia .05 g/mL Injection?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| English Walnut Pollen .05 g/mLthis 49643-0367-05 | Allermed | 5 ml | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Purple Book · refreshed Nov 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Where does this data come from?
- FDA Purple Book · refreshed Nov 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
0.53 g / 1 mL
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
-
0.004 g / 1 mL
UNII 339NCG44TV
Phenol is a chemical compound derived from coal tar or petroleum. It serves as a preservative and antimicrobial agent in medicines, helping prevent bacterial and fungal growth to keep the product stable and safe during storage.
-
0.00125 g / 1 mL
UNII 8MDF5V39QO
A white powder form of baking soda that acts as a buffer and pH regulator in medicines. It helps maintain the right acid-base balance and may aid tablet disintegration.
-
0.0025 g / 1 mL
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
5 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Allermed Laboratories, Inc. labeler code 49643
- Velvet Grass Pollen Holcus lanatus .05 g/mL Injection NDC 49643-361-05
- Burrobrush Pollen Hymenoclea salsola .05 g/mL Injection NDC 49643-362-05
- Poverty Weed Pollen Iva axillaris .05 g/mL Injection NDC 49643-363-05
- Rough Marshelder Pollen Iva ciliata .05 g/mL Injection NDC 49643-364-05
- Burweed Marshelder Pollen Iva xanthifolia .05 g/mL Injection NDC 49643-365-05
- Black Walnut Pollen Juglans nigra .05 g/mL Injection NDC 49643-366-05
- California Juniper Pollen Juniperus californica .05 g/mL Injection NDC 49643-368-05
- Western Juniper Pollen Juniperus occidentalis .05 g/mL Injection NDC 49643-369-05
- Utah Juniper Pollen Juniperus osteosperma .05 g/mL Injection NDC 49643-370-05
- Mountain Cedar Pollen Juniperus sabinoides .05 g/mL Injection NDC 49643-371-05
- Rocky Mtn. Juniper Pollen Juniperus scopulorum .05 g/mL Injection NDC 49643-372-05
- Red Cedar Pollen Juniperus virginiana .05 g/mL Injection NDC 49643-373-05
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
🚨 Boxed Warning ▾
WARNINGS This allergenic product is intended for use by physicians who are experienced in the administration of allergenic extracts, and the emergency care of anaphylaxis, or for use under the guidance of an allergy specialist. This allergenic extract is not directly interchangeable with other allergenic extracts. The initial dose must be based on skin testing as described in the dosage and administration section of this insert.
Patients being switched from other types of extracts, such as alum precipitated extracts, should be started as though they were coming under treatment for the first time. Patients should be instructed to recognize adverse reaction symptoms and cautioned to contact the physician's office if reaction symptoms occur. As with all allergenic extracts, severe systemic reactions may occur.
In certain individuals these systemic reactions may occur. In certain individuals these reactions may be life threatening. Patients should be observed for at least 20 minutes following treatment, and emergency measures as well as personnel trained in their use should be immediately available in the event of a life threatening reaction.
This product should not be injected intravenously (see Dosage and Administration). Refer also to the Warnings, Precautions, Adverse Reactions and Overdosage sections below.
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Allergenic extract may be used as a diagnostic skin test reagent in persons suspected of being sensitive to the allergenic source material from which the extract is made. Skin tests should be used in conjunction with a thorough allergic history to establish the relevance of a given allergen in the etiology of allergic disease. (4,5,6) Immunotherapy with allergenic extract is indicated in persons suffering from allergic rhinitis, bronchitis, conjunctivitis, urticaria and asthma.
The therapeutic efficacy of allergenic extract has been proven in ragweed, grass, and mountain cedar pollinosis, cat-induced asthma and hypersensitivity to hymenoptera venoms. (7-12) Immunotherapy may be used along with or exclusive of antihistamines and other medications used to control allergic symptoms.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Diagnosis : Concentrated extract may be used for scratch or prick testing providing the patient is not extremely sensitive. In this case, the extract should be diluted 10 fold before a scratch or prick test is performed. Extract for intradermal testing must be used as follows: a.
Patients with positive scratch or prick tests : It is not advisable to perform an intradermal skin test if the patient has a positive scratch or prick test. b. Patients with a negative scratch or prick test : Patients who do not react to a valid scratch or prick test should be tested intradermally with 0.05 mL of a 1:1000 v/v dilution of the concentrate. If the test is negative, a second test should be performed with 0.05 mL of a 1:100 v/v dilution of concentrate. c.
Patients tested only by the intradermal method : Patients suspected of being highly allergic should be tested with 0.05 mL of a 1:100,000 v/v dilution of the concentrate. A negative test should be followed by repeat tests using 10 fold stronger concentrations until the maximum dose of 0.05 mL of a 1:100 v/v dilution is reached. Interpretation of Results Scratch and Prick Test A negative test shows only a slight red area at the site of scarification or prick penetration.
Positive tests are scored as follows: 1+ Erythema with 5 mm wheal 2+ Erythema with a 5-10 mm wheal 3+ Erythema with a 10-15 mm wheal 4+ Erythema with a wheal 15 mm (or larger) with pseudopodia Intradermal Test A negative test shows no change in the appearance and size of the 5 mm wheal created by the I.D. injection of 0.05 mL of extract. Positive tests are scored as follows: 1+ Erythema 10-20 mm with a 5-10 mm wheal 2+ Erythema 20-30 mm with a 5-10 mm wheal 3+ Erythema 30-40 mm with a 10-15 mm wheal 4+ Erythema greater than 40 mm with a 15 mm wheal (or larger) with pseudopodia Immunotherapy Allergenic extract should be administered subcutaneously in the outer aspect of the upper arm using a sterile tuberculin syringe and needle.
The skin should be cleaned with 70% alcohol and aseptic technique should be observed in removing the extract from the vial. Care must be taken to avoid injecting the extract into a blood vessel because of the risk of anaphylaxis. Concentrated extract must be diluted before administration to new patients.
A 1:100,000 v/v dilution of concentrate is usually satisfactory to start treatment. However, as a precaution against overdose, a skin test with the intended starting dose should be done to help evaluate the patient's sensitivity to the product. If the skin response is larger than 5 mm edema/15 mm erythema, the extract is too strong and must be diluted before it is given subcutaneously.
The doses shown in the Suggested Dosage Schedule below are recommended unless the patient's skin test response and allergic history indicates that more dilute extract should be used. Little is known about the required accumulated dosage of allergen that is needed to relieve symptoms. However , studies have shown that high dose immunotherapy is efficacious in the treatment of allergic rhinitis and asthma.
For this reason, treatment with extract from Vial #5 is recommended, providing the patient can tolerate the extract without experiencing local or systemic reactions. Treatment with Vial #6 may be used for patients who have not had adverse reactions to extract in Vial #5 and who require more concentrated extract to control or relieve symptoms. Patients who have received allergenic extract for maintenance therapy SHOULD NOT be given the same dose from a fresh vial of extract.
IT IS ADVISABLE TO REDUCE THE DOSAGE OF FRESH EXTRACT TO ONE-FOURTH THE AMOUNT GIVEN FROM A PREVIOUS LOT OF EXTRACT MADE AT THE SAME CONCENTRATION AND BY THE SAME FORMULA. Suggested Dosage Schedule No. Vial #1 1:100,000 w/v frequency twice weekly mL Vial #2 1:10,000 w/v frequency twice weekly mL Vial #3 1:1,000 w/v frequency once weekly mL Vial #4 1:100 w/v frequency once weekly mL Vial #5 1:10 w/v frequency every two-fou… [Excerpted — this section continues on DailyMed.]
⛔ Contraindications ▾
CONTRAINDICATIONS Allergenic extract should not be administered to a non-allergic person. However, there are no absolute contraindications to the use of allergenic extract for treatment in appropriate individuals. Relative contraindications include: EXTREME SENSITIVITY TO AN ALLERGEN - Determined from the allergic history, or from previous anaphylaxis following skin testing or subcutaneous injection; AUTOIMMUNE DISEASE - Individuals with autoimmune disease may be at risk, due to the possibility of routine immunizations exacerbating symptoms of the underlying disease; PREGNANCY - In limited controlled studies of women receiving allergenic extract during conception and throughout all trimesters of pregnancy, no evidence was found that extract is harmful to the fetus or mother.
However, because of the known pharmacologic action of histamine on uterine muscle, any treatment that might result in the release of significant amounts of this mediator should be avoided if possible (13). See Precaution #4; MYOCARDIAL INFARCTION - Patients who have experienced a recent myocardial infarction may not be able to tolerate immunotherapy. As in all of the above circumstances, the benefit to risk ration must be carefully evaluated; BLEEDING DIATHESIS - Patients with a bleeding tendency should not be tested or treated with allergenic extract, unless the physician responsible believes that such procedures are safe to perform.
Allergenic extract should be temporarily withheld from patients if any of the following conditions exist: (1) severe symptoms of hay fever and/or asthma; (2) infection or flu accompanied by fever; and (3) exposure to excessive amounts of clinically relevant allergens prior to skin testing or immunotherapy.
⚠️ Warnings ▾
WARNINGS The only approved method approved for determining hypersensitivity to Allermed Laboratories Allergenic Extracts is by diagnostic skin testing (See DOSAGE AND ADMINISTRATION - DIAGNOSIS). Physicians who administer allergenic extrract should have emergency medication and equipment available to treat anaphylaxis (14). See Precautions, Adverse Reactions and Overdosage below.
To reduce the risk of anaphylaxis, the following measures must be observed. 1. Concentrated extract must be diluted before use for intradermal skin testing and for beginning immunotherapy.
It should never be in injected intravenously during testing or treatment procedures. 2. Patients who are highly sensitive, determined from clinical findings and test results, may require that treatment start with a very weak concentration of extract, such as 1:10,000,000 v/v.
3. The dosage of fresh (new) extract given to a patient receing maintenance injections must be reduced to one-fourth the amount given from the previous (old) lot (See Immunotherapy, last paragraph). 4.
Patients who are transferred to standardized extract after previous treatment with unstandardized extract must bew skin tested with serial dilutions, starting with a 1:100,000 v/v dilution of hte standardized extract, to determine a safe, non-reacting starting dose. 5. Patients who are transferred to this extract treatment with alum precipiated or other modified extract must re-start injections with the beginning recommended dose of this extract.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Local Reactions : The occurrence of a hive 5 to 15 minutes after the subcutaneous injection of extract does not require a reduction in dosage. However, a local reaction with edema larger than 2 cm in diameter or swelling and redness that persist for several hours or longer indicates that too much extract has been given. Treatment should be altered as follows: Additional injections should not be given until all evidence of the reaction has disappeared.
The next injection administered should be 50% of the last non-reacting dose or less, depending upon the size and severity of the local reaction. Subsequent injections should be continued at the reduced dosage unless the physician responsible for treatment believes that it is safe to increase the dose, and that possible clinical improvement would result form the administration of a larger dose of extract. Systemic Reactions :Systemic (generalized) reactions may range from a mild exacerbation of the patient's allergic symptoms to hives, anaphylactic shock, or even death from anaphylaxis.
The reaction usually occurs 5 to 20 minutes after injection. As a rule, the more quickly a reaction develops, the more serious it is likely to become. Symptoms may include sneezing, coughing, itching, shortness of breath, abdominal cramps, vomiting, diarrhea, tachycardia, hypotension and respiratory failure in severe cases.
The reaction is usually stopped by the subcutaneous injection of Epinephrine HCL 1:1,000 (See Overdosage below). The oral administration of antihistamines and the placement of a tourniquet proximal to the injection site are helpful adjuncts. In the event that additional measures are required, it may be necessary to treat the patient for BRONCHOSPASM with intravenous aminophylline, intravenous fluids and corticosteroids; for HYPOTENSION with vasopressors, volume repletion, isoproterenol and corticosteroids; for LARYNGEAL OBSTRUCTION with oxygen and tracheostomy and for CARDIAC ARREST with cardiopulmonary resuscitation and other appropriate measures.
Immunotherapy after anaphylaxis should be continued if the cause of the reaction can be identified and appropriate precautions taken to insure that a subsequent reaction does not occur.
🆘 Overdosage ▾
OVERDOSAGE A strong local reaction to the injection of extract may be treated with oral antihistamines and the local application of a cold compress. The dosage must be reduced and additional extract must not be given until all evidence of the reaction has disappeared. A systemic reaction following the injection of extract must be treated immediately as follows (Ref. #4, vol.
2, p. 888): 0.01 mL/kg up to 0.2 mL of aqueous epinephrine HCl 1:1000 subcutaneously at the injection site of antigen. 0.01 mL/kg up to 0.3 mL of aqueous epinephrine HCl 1:1000 subcutaneously at another site.
Diphenhydramine intravenously or intramuscularly, 1.25 mg/kg up to 50 mg. Tourniquet above the injection site of antigen. Specific reactions: Brochospasm: intravenous aminophylline 4 mg/kg up to 500 mg given over 10 to 15 minutes, aqueous hydrocortisone 5 mg/kg up to 200 mg, oxygen.
Laryngeal edema: oxygen, intubation, tracheostomy. Hypotension: vasopressors, fluids, corticosteroids. Cardiac arrest: resuscitation, sodium bicarbonate, defibrillation, antiarrhythmia medications.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Positive skin tests with allergenic extract are the result of histamine release from mast cells sensitized with allergen specific IgE. The exact mechanisms by which immunotherapy relieves symptoms of allergy are still under investigation. Elevations in allergen-specific IgG antibodies and an increase in the activity of T suppressor lymphocytes appear to be some of the immunologic changes that occur from hyposensitization. (1,2,3)
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Allergenic extract is supplied in 5 mL dropper vials for scratch or prick testing and in 10, 30, and 50 mL vials for bulk use.
📦 Storage and Handling ▾
STORAGE AND HANDLING Extract should be stored at 2-8°C since higher temperatures may adversely affect stability. Do not freeze.
📋 Description ▾
DESCRIPTION Allergenic extract contains the aqueous extractables from allergenic source material in extracting solution containing 0.25% sodium chloride, 0.125% sodium bicarbonate, and 50% glycerol. 0.4% phenol is added as a preservative. The weight by volume value shown on the label is a measurement of extract concentration, rather than extract potency. Extracts for which U.S. standards exist are labeled in allergy units, in addition to w/v strength.
⚠️ Precautions ▾
PRECAUTIONS Extract should be stored at 2°C to 8°C since higher temperatures may adversely affect the stability of the product. Do not freeze. After the needle is inserted subcutaneously, the plunger should be withdrawn slightly to check for the presence of blood in the syringe.
If blood is observed, a new injection should be prepared and given at another site, observing the same precautions. Treatment with beta-blocking drugs may make patients refractory to the usual dose of epinephrine, in the event epinephrine is required to control an adverse allergic reaction. PREGNANCY CATEGORY C.
Allergenic extract. Animal reproduction studies have not been conducted with allergenic extract. It is also not known whether allergenic extract can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
Allergenic extract should be given to a pregnant woman only if clearly needed. PATIENT INSTRUCTIONS: Patients should be instructed to remain in the physician's office for at least 20 minutes after skin testing and after each treatment injection, and immediately notify the physician if symptoms of a generalized reaction or shock occur. CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Long term studies have not been conducted with allergenic extracts to determine their potential for carcinogenesis, mutagenesis, and impairment of fertility.
LACTATION: Data are not available on the secretion of allergenic extract in human milk and it is not known what affect this might have on the nursing infant. PEDIATRIC USE: The dose of allergenic extract recommended for children is the same as that used for adults, except in the injection of large doses of extract for treatment. In this case, the amount of extract given to a child may be modified so that the discomfort of the injection is minimized.
📚 References ▾
REFERENCES 1. Levy, D.A., Lichtenstein, L.M., Goldstein, E.O. and Ishizaka, K. Immunologic and cellular changes accompanying the therapy of pollen allergy.
J. Clinical Investigations. 50:360, 1971.
2. Evans, R., Pence, H., Kaplan, H., and Rocklin, R. The effect of immunotherapy on humoral and cellular response in ragweed hayfever.
J. Clinical Investigations. 57:1378, 1976.
3. Ishizaka, K. Cellular events in the IgE antibody response.
Adv. In Immunology. 23:50, 1976.
4. Middleton, Elliott Jr., Reed, C.E. and Ellis, E.F. (Eds.) Allergy, Principles and Practice Vols.
1 & 2, C.V. Mosby 1978. 5.
Sheldon, J.M., Lovell, R.G. and Matthews, K.P. A Manual of Clinical Allergy. W.B.
Saunders, 1967. 6. Nelson, H.S.
Diagnostic procedures in allergy. I. Allergy skin testing.
Ann. Allergy. 51:411, 1983.
7. Norma, P.S., Winkenwerder, W.L., and Lichtenstein, L.M. Immunotherapy of hay fever with ragweed antigen E: comparisons with whole pollen extract and placebos.
J. Allergy. 42:93, 1968.
8. Milner, F.H. and Tees, E.C. Specific sensitivity to individual grass pollens in some hay fever patients.
Clinical Allergy. 2:83, 1972. 9.
Frankland, A.W. and Augustine, R. Grass pollen antigens effective in treatment. Clinical Science.
23:95, 1962. 10. Pence, H.L., Mitchell, D.Q., Greely, R.L., Updegraff, B.R. and Selfridge, H.A.
Immunotherapy for mountain cedar pollinosis: a double-blind controlled study. J. Allergy ad Clinical Immunology.
58:39, 1976. 11. Taylor, W.W., Ohman, J.L.
Jr. and Lowell, F.C. Immunotherapy in cat- induced asthma. Double-blind trial with evaluation of bronchial responses to cat allergen and histamine.
J. Allergy and Clinical Immunology. 61:283.
1978. 12. Lichtenstein, L.M., Valentine, M.D. and Sobotka, A.K.
Insect allergies. The state of the art. J.
Allergy and Clinical Immunology. 61:268, 1978. 13.
Metzger, W.J., Turner, E., and Patterson, R. The safety of immunotherapy during pregnancy. J.
Allergy and Clinical Immunology. 61:268. 1978.
14. Ouellette, J.J. Emergency management of allergic reactions.
Modern Medicine 99, 1975.
📄 Package Label / Principal Display Panel ▾
Container Label Sample Container Label
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |